ArticleMolecular biotechnology2025

Identification of CXCL13 as a Promising Biomarker for Immune Checkpoint Blockade Therapy and PARP Inhibitor Therapy in Ovarian Cancer.

Yue Ding et al.PubMed ↗Publisher ↗

No numbers read from the abstract.